Lilly, Incyte get FDA breakthrough therapy status for baricitinib to treat alopecia areata

Eli Lilly and Incyte have secured a breakthrough therapy designation from the US Food and Drug Administration (FDA) for baricitinib to treat alopecia areata (AA).